Postgrad LIVE! Study Fairs

Bristol

Coventry University Featured PhD Programmes
University of Portsmouth Featured PhD Programmes
FindA University Ltd Featured PhD Programmes
University of Glasgow Featured PhD Programmes
Queen’s University Belfast Featured PhD Programmes
United Kingdom
Leeds×
10 miles

Pharmacology / Toxicology PhD Projects, Programs & Scholarships in Leeds

We have 31 Pharmacology / Toxicology PhD Projects, Programs & Scholarships in Leeds

  • Pharmacology / Toxicology×
  • United Kingdom×
  • Leeds×
  • clear all
Order by 
Showing 1 to 10 of 31
  Targeting addiction to a breast cancer metastasis survival pathway by inhibition of RAN GTPase
  Research Group: Institute of Cancer Therapeutics
  Dr S Shnyder, Prof M El-Tanani, Dr S Betmouni
Applications accepted all year round
Metastatic cancer is a major global health burden. Each year, eleven million new cases of cancer are diagnosed worldwide, including 5 million cases in industrialized countries.
  Ran GTPase as a potential novel therapeutic target in EMT transdifferentiation and breast cancer stem cell (BCSC) survival during metastatic development
  Research Group: Institute of Cancer Therapeutics
  Prof R Morgan, Prof M El-Tanani, Dr M Isreb, Dr M Najafzadeh
Applications accepted all year round
Breast cancer is the leading cause of cancer death in women worldwide. Accumulating evidence suggests that local disease recurrence and metastatic lesions, the major causes of patient mortality, are due to a subset of aggressive cells termed cancer stem cells (CSCs).
  Re-purposing established drugs for the resolution of pulmonary arterial hypertension (PAH)
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Impact of RhoA deregulation on smooth muscle cell phenotypic dysfunction in Type 2 diabetes
  Research Group: Chemistry and Biosciences
  Dr K Riches-Suman
Applications accepted all year round
Type 2 diabetes (T2D) is an escalating healthcare burden. It inflicts significant physical and emotional distress on patients and their carers, and treatment of T2D and its complications accounts for ~10% of the entire NHS budget.
  Aldehyde dehydrogenase expression and function in cancer stem cells
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Dr A Mardaryev, Prof A Locke
Applications accepted all year round
Aldehyde dehydrogenases (ALDHs) catalyse the oxidation and detoxification of reactive endogenous and exogenous aldehydes into carboxylic acids via NAD+ coupled reduction.
  Pharmaceutical cocrystallisation for improved medicines
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr V Vangala, Prof A Paradkar
Applications accepted all year round
Active pharmaceutical ingredients (APIs) are frequently delivered to the patients in the solid-state formulation. Yet, therapeutic effectiveness of a dosage form depends on the bioavailability, stability and also on the manufacturability of the dosage form.
  Identifying glucose-dependent mechanisms underlying risk factors for Alzheimer’s disease
  Research Group: Pharmacology and Experimental Therapeutics
  Dr R Williamson, Dr S McLean
Applications accepted all year round
Several risk factors for Alzheimer’s disease including diabetes and midlife obesity are age-dependent and have an obvious metabolic component resulting in impaired glucose metabolism.
  Determining brain glycosylation in ageing and Alzheimer’s disease
  Research Group: Pharmacology and Experimental Therapeutics
  Dr R Williamson, Dr C Sutton
Applications accepted all year round
Increasing age is associated with lower levels of cognitive performance; concomitant with this is a decrease in brain glucose metabolism.
  Therapeutic resolution of pulmonary arterial hypertension (PAH) by natural products
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof C Wright
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Quantitative structure/skin-permeation relationships (QSPeRs); an investigation of the relevance of parameters determined with biomembrane-mimicking systems for the predictability of drug partitioning into skin
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr X Liu, Prof D J Tobin
Applications accepted all year round
The transdermal route has many advantages over other routes for the delivery of drugs with systemic activity. These include the ease of use (and withdrawal in the occurrence of side-effects), avoidance of first-pass metabolism, and improved patient compliance.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.